S. L. Graziano

Randomized Phase III Intergroup Trial of Isotretinoin to Prevent Second Primary Tumors in Stage I Non-Small-Cell Lung Cancer

Scott M. Lippman, J. Jack Lee, Daniel D. Karp et al. · JNCI Journal of the National Cancer Institute · 2001 · 319 citations · Full text

Interim report of on-study demographics and toxicity from E1505, a phase III randomized trial of adjuvant (adj) chemotherapy (chemo) with or without bevacizumab (B) for completely resected early-stage non-small cell lung cancer (NSCLC).

Heather A. Wakelee, Suzanne E. Dahlberg, S.M. Keller et al. · Journal of Clinical Oncology · 2011 · 32 citations

Preclinical Therapeutics, Surgical Oncology, Early Stage Nsclc +20

Adjuvant chemotherapy (AC) in stage IB non-small cell lung cancer (NSCLC): Long-term follow-up of Cancer and Leukemia Group B (CALGB) 9633.

Gary M. Strauss, X. F. Wang, Michael A. Maddaus et al. · Journal of Clinical Oncology · 2011 · 18 citations

Surgical Oncology, Cancer Management, Immunology +18

Impact of <i>KRAS</i> mutations on adjuvant carboplatin/paclitaxel in surgically resected stage IB NSCLC: CALGB 9633.

Marzia Capelletti, X. F. Wang, L. Gu et al. · Journal of Clinical Oncology · 2010 · 17 citations

Kras Mutations, Adjuvant Carboplatin/paclitaxel, Surgical Oncology +14

Immunohistochemical evaluation of E-cadherin and epidermal growth factor receptor in non-small cell lung cancer.

Steven Sorscher, V Russack, S. L. Graziano et al. · PubMed · 1995 · 15 citations